Here's What Key Metrics Tell Us About GoodRx (GDRX) Q4 Earnings

GoodRx Holdings, Inc. (GDRX) reported $194.79 million in revenue for the quarter ended December 2025, representing a year-over-year decline of 1.9%. EPS of $0.09 for the same period compares to $0.09 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $192.06 million, representing a surprise of +1.42%. The company delivered an EPS surprise of +2.27%, with the consensus EPS estimate being $0.09.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how GoodRx performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Monthly Active Consumers: 5 versus the three-analyst average estimate of 5.
• Subscription plans: 674 compared to the 667 average estimate based on two analysts.
• Revenue- Prescription transactions: $124.72 million versus $127.68 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -14% change.
• Revenue- Other: $4.1 million versus the four-analyst average estimate of $4.41 million. The reported number represents a year-over-year change of -15.1%.
• Revenue- Subscription: $21.58 million versus $20.59 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +4.4% change.

View all Key Company Metrics for GoodRx here>>>

Shares of GoodRx have returned +4.7% over the past month versus the Zacks S&P 500 composite's +0.6% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

 
GoodRx Holdings, Inc. (GDRX): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research